Navigation Links
Transgenomic Announces Closing of the Acquisition of Clinical Data's Diagnostic Business and the Closing of a $6 Million Financing
Date:12/29/2010

addition, HANABI automated chromosome harvesting systems improve laboratory productivity with consistent quality compared with manual methods for cytogenetic analyses. Service offerings include the Transgenomic Molecular Laboratory, which provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases. Transgenomic Pharmacogenomics Services is a CRO for pharmacogenomic, translational research and clinical trials.

Forward Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements relate to a variety of matters, including but not limited to: the benefits and synergies expected to result from the asset acquisition; the anticipated customer base for Transgenomic following the completion of the asset acquisition; and other statements that are not purely statements of historical fact. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Transgenomic and are subject to significant risks and uncertainty.   Investors are cautioned not to place undue reliance on any such forward-looking statements.  All such forward-looking statements speak only as of the date they are made, and Transgenomic undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise.  Factors that could cause actual results to differ materially from the forward-looking statements contained herein include, but are not limited to: any operational or cultural difficulties associated with the integration of the assets being acquired; potential adverse reactions or changes to business relationships resulting from the announcement or completion of the asset acquisition; unexpected costs,
'/>"/>

SOURCE Transgenomic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Transgenomic Expands Distribution of SURVEYOR® Scan K-RAS Mutation Detection Kit With CE IVD Mark
2. Transgenomic to Present at the Rodman & Renshaw 12th Annual Global Investment Conference
3. Transgenomic to Present at the Noble Financial Sixth Annual Equity Conference - ONTRACK 2010
4. Transgenomic Reports Fourth Quarter Financial Results
5. Transgenomic Demonstrates Very High Sensitivity Detection of Tumor-Associated KRAS Mutations in Matched Plasma Samples Using COLD-PCR
6. Transgenomic, Inc. Executes License Option agreement for Parkinsons Disease Diagnostic Markers with Gene Solutions, LLC
7. Reminder Webcast Alert: Transgenomic, Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
8. Webcast Alert: Transgenomic Inc. Announces Third Quarter 2009 Earnings Release Conference Call Webcast
9. Transgenomic Signs Exclusive License for Cold-PCR Technology From the Dana-Farber Cancer Institute
10. Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test
11. Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... Reportlinker.com announces that ... its catalogue: Antibody Drug Conjugates Market ... http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html INTRODUCTION Antibody ... therapeutic agents, gaining increasing attention from both large ... marriage of an antibody with a toxic drug ...
(Date:8/30/2014)...   Royal Philips  (NYSE: PHG, AEX: PHIA) today ... ultrasound system designed to enable global hospitals and health ... and cost pressures. Making its debut at the  European ... Barcelona this week, Affiniti provides innovative technology ... resources deliver high quality patient care. ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- SAM ... (Axilla) Strap for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today that ... recall to address a potential issue with a ... for the Axilla application of the SAM Junctional ...
Breaking Medicine Technology:Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2
... Sinovac Biotech Ltd. (Nasdaq: SVA ), a ... its preliminary unaudited sales range for the third quarter ... full year 2010. A conference call to discuss these ... on October 25, 2010 at 8:00 a.m. Eastern Time ...
... Oct. 23 Optimer Pharmaceuticals, Inc. (Nasdaq: ... from its two fidaxomicin Phase 3 trials in patients ... 48th Annual Meeting of the Infectious Disease Society of ... oral presentation, investigator Derrick Crook, M.D., of the University ...
Cached Medicine Technology:Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations 2Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations 3Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations 4Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 2Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 3Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 4Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA 5
(Date:9/1/2014)... Wellesley, Mass., (PRWEB) September 01, 2014 ... report, BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS ... reached $21.8 million in 2013 and is expected to ... further grow to $471.5 million by 2019, which is ... 2014 through 2019. The receptor-mediated transport (RMT) segment is ...
(Date:9/1/2014)... 2014 Parties involved in federally-filed Tylenol ... litigation’s status conference in September, where issues related to ... the Eastern District of Pennsylvania, Bernstein Liebhard LLP reports. ... posted on the Court’s website, the meeting is scheduled ... a.m. This is the latest of several Tylenol conferences ...
(Date:9/1/2014)... Ontraport , one of the latest ... to automate the small intricacies of managing an online ... prompting an investigative review. , “As a new ... all of the small details involved with running a ... “That’s why Ontraport has become so popular in this ...
(Date:9/1/2014)... AttorneyOne.com, a recognized authority on law, update ... the FDA on DePuy Synthes Craniomaxillofacial Distraction System ... 28, that specific lots of DePuy Synthes Craniomaxillofacial Distraction ... device may reverse directions after surgery. According to ... is an implant used to lengthen and/or stabilize the ...
(Date:9/1/2014)... 01, 2014 Beginning Tuesday, September 2nd, ... medical professionals and 10,000 consumers for the annual gathering ... gathering of the nation’s top medical professionals who specializes ... conditions. The week-long event contains more than 120 hours ... available in the pain management field. , MarijuanaDoctors.com is ...
Breaking Medicine News(10 mins):Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3Health News:Medical Marijuana Doctor Company Set to Present at Las Vegas Pain Week 2
... the largest study of its kind for the genetic roots ... Disease as well as further evidence that some people of ... study examined changes in DNA associated with the two most ... which is most frequently marked by inflammation of the final ...
... Assessment Tools To ... Healthier Lifestyles, NEW YORK, March 26 EnergyNow!, ... and fitness,technology fields, today announced the availability of a ... Delaware, Maryland,Pennsylvania, Virginia, West Virginia and Washington D.C. combat ...
... Governor Edward G.,Rendell today announced the state,s new ... ahead to better meet their future,long-term care needs., ... be put off. If,people do fail to prepare, it ... "The ,Own Your Future, campaign,empowers consumers to take steps ...
... Award-Winning Mind Fitness Company, WASHINGTON, March 26 ... Ltd., the company that uses the latest scientific,research ... cognitive,performance and health, today announced that it will ... the American Society on Aging,(ASA), as a consultant., ...
... Technologies(R),Inc. ("Global Med" or the "Company") (OTC Bulletin ... announced,the sale yesterday, March 25, 2008, of approximately ... was held by SingXpress Ltd., an Asian company,(previously ... were sold,to five American institutions and the transaction ...
... lower health-related quality of life for their children ... from the parents of healthy children. However, reports ... These findings are published in the April issue ... online at Wiley Interscience (www.interscience.wiley.com ). , Children ...
Cached Medicine News:Health News:Large multicenter study suggests new genetic markers for Crohn's disease 2Health News:EnergyNow! Announces New Grant Funding to Combat Childhood Obesity 2Health News:EnergyNow! Announces New Grant Funding to Combat Childhood Obesity 3Health News:Governor Rendell Announces 'Own Your Future' Campaign; Urges Consumers to Better Plan Their Long-Term Care Needs 2Health News:CogniFit to Work With Gloria Cavanaugh, Former ASA President 2Health News:Global Med Technologies(R), Inc. Announces the Sale of Approximately 3.3 Million Shares of Global Med Common Stock Held by SingXpress Ltd., an Asian Company, to Five American Institutions 2Health News:Study shows lifetime effects of pediatric liver transplants 2
... Lyphochek Immunoassay Plus Control provides ... comprehensive control in the world for ... procedures, eliminating the need for separate ... no added preservatives, it is suitable ...
... Plus Control is a liquid ... today's busy immunoassay laboratory. With ... human serum based control can ... control products for immunoassay and ...
Liquichek Immunology Control is a trilevel, liquid, comprehensive serum protein control with assayed values for a wide number of methods....
... Detection Platform provides fully automated detection of ... platform for molecular pathology labs separates DNA ... features that deliver a high degree of ... the capacity to run two 96-well plates, ...
Medicine Products: